Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The research shows how certain drug molecules form stable structures with polymers, which could help create new drug forms.

Method B with propylene glycol is better for stable low-concentration DPCP solutions for alopecia areata.

Obesity is linked to higher metabolic syndrome and LH/FSH ratios, but no significant differences exist among PCOS phenotypes.

Chemotherapy harms healthy cells, causing side effects like hair loss and reduced immunity.

Encapsulating hair loss drugs in cyclodextrins improves their solubility and reduces scalp irritation.

TLR3 signaling enhances the immunosuppressive properties of human periodontal ligament stem cells.

Hair microscopy is a useful and affordable way to diagnose hair disorders.

New techniques make hair transplants look more natural.

Keratin 15 affects cell behavior and characteristics in skin cells.

The SAAD-41 is a valid tool for assessing distress in people with Alopecia Areata.

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

A new tool simplifies alopecia areata severity scoring but needs validation.

The Arabic Skindex-16 is a reliable and valid way to measure the impact of skin conditions on quality of life in Saudi patients.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

A SALT score of ≤ 20 indicates meaningful improvement in alopecia areata treatment.

Higher antigliadin antibody levels are linked to alopecia areata severity.

Adults with alopecia areata stick to their medication better than those with atopic dermatitis.

Baricitinib significantly regrows hair in severe alopecia areata patients.

AI can accurately measure hair loss severity in alopecia areata.

Baricitinib works better in adolescents than adults for treating severe alopecia areata.

Higher antigliadin antibodies are linked to more severe alopecia areata, suggesting screening for celiac disease in these patients.

Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.

Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.

The Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata from other hair loss types but needs more validation.

A change in SALT scores of 42 or 43 indicates meaningful improvement in alopecia areata treatment.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.

The Turkish version of the Alopecia Areata Quality of Life Index is reliable and valid.